XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.22.4

Inventory | 12 Months Ended
--- | ---
Dec. 31, 2022
Inventory |
Inventory | 4.Inventory Inventory consisted of the following:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31,
(in thousands) | ​ | 2022 | ​ | 2021
Raw materials | ​ | $ | 10,262 | ​ | $ | 4,870
Work in process | ​ |  | 86,712 | ​ |  | 65,117
Finished goods | ​ |  | 18,077 | ​ |  | 23,265
Total | ​ | $ | 115,051 | ​ | $ | 93,252
​ The Company began capitalizing YUSIMRY inventory in the second quarter of 2022 and had $23.7 million of such inventory recognized in the consolidated balance sheets at December 31, 2022. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current in the consolidated balance sheets. As of December 31, 2022 and 2021, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following table presents the inventory balance sheet classifications: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31,
(in thousands) | ​ | 2022 | ​ | 2021
Inventory | ​ | $ | 38,791 | ​ | $ | 37,642
Inventory, non-current | ​ |  | 76,260 | ​ |  | 55,610
Total | ​ | $ | 115,051 | ​ | $ | 93,252
​ Prepaid manufacturing of $17.9 million as of December 31, 2022 includes prepayments of $13.0 million to CMOs for manufacturing services of the Company’s products, which the Company expects to be converted into inventory during 2023; and prepayments of $4.9 million to various CMOs for research and development pipeline programs. Prepaid manufacturing of $13.7 million as of December 31, 2021 includes prepayments of $8.3 million to a CMO for manufacturing services for UDENYCA; and prepayments of $5.4 million to various CMOs for other research and development pipeline programs. ​ In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea as part of a realignment of research and development resources toward other development programs. As a result, the Company recognized $11.2 million within research and development expense in the consolidated statement of operations in 2021, which included an impairment charge of $3.2 million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. No material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021. ​

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI https://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration